Corpus overview


Overview

MeSH Disease

Anorexia (31)

COVID-19 (30)

Dyspnea (17)

Fever (16)

Fatigue (16)


HGNC Genes

SARS-CoV-2 proteins

There are no SARS-CoV-2 protein terms in the subcorpus


Filter

Genes
Diseases
SARS-CoV-2 Proteins
    displaying 1 - 10 records in total 31
    records per page




    COVID-19 MESHD-Related Symptoms Among Cancer MESHD Patients and Healthcare Workers— First Results From the PAPESCO-19 Prospective Cohort Study

    Authors: Ke Zhou; Audrey Blanc-Lapierre; Valérie Seegers; Michèle Boisdron-Celle; Frédéric Bigot; Marianne Bourdon; Hakim Mahammedi; Aurélien Lambert; Mario Campone; Martine Bellanger; Jean-Luc Raoul

    id:10.20944/preprints202103.0292.v1 Date: 2021-03-10 Source: Preprints.org

    Background: Cancer MESHD patients may fail to distinguish COVID-19 MESHD symptoms such as anosmia MESHD, dysgeusia/ageusia MESHD, anorexia MESHD, headache MESHD, and fatigue MESHD, which are frequent after cancer MESHD treatments. We aimed to identify symptoms associated with COVID-19 MESHD and to assess the strength of their association in cancer MESHD and cancer MESHD-free populations. Methods: The prospective multicenter cohort study PAPESCO-19 included 878 cancer MESHD patients and 940 healthcare workers (HCWs) systematically tested for SARS-CoV-2-specific antibodies. Participants reported the results of routine screening RT-PCR and thirteen COVID-19 MESHD symptoms. Backward logistic regression identified the symptom combinations significantly associated with COVID-19 MESHD. Results: COVID+ proportions were similar in patients (8%) and HCWs (9.5%, p=0.26), whereas symptomatic proportions were lower in patients (32%) than HCWs (52%, p<0.001). Anosmia MESHD, anorexia MESHD, fever MESHD, headache MESHD, and rhinorrhea MESHD together accurately discriminated (c-statistic=0.7027) COVID-19 MESHD cases in patients. Anosmia, dysgeusia/ageusia MESHD, muscle pain MESHD, intense fatigue MESHD, headache MESHD, and chest pain MESHD better discriminated (c-statistic=0.8830) COVID-19 MESHD cases in HCWs. Anosmia had the strongest association in patients (OR=7.48, 95% CI: 2.96–18.89) and HCWs (OR=5.71, 95% CI: 2.21–14.75). Conclusions: COVID-19 MESHD symptoms and their diagnostic performance differ in cancer MESHD patients and HCWs. Anosmia is associated with COVID-19 MESHD for patients, while dysgeusia MESHD/ageusia are not. Cancer MESHD patients deserve tailored preventive measures due to their particular COVID-19 MESHD symptom pattern.

    Symptomatic Features of 932 Hospitalized Patients with COVID-19 MESHD in Wuhan

    Authors: Liang-Liang Sun; Jian Wang; Yu-Sheng Wang; Ping-Fang Hu; Zheng-Qing Zhao; Wei Chen; Bei-Fang Ning; Chuan Yin; Yu-Shi Hao; Qiong Wang; Chen Wang; Ya-Long Liu; Cheng Chen; Ji-Zhong Yin; Hai Huang; Wei-Fen Xie

    doi:10.21203/rs.3.rs-148616/v1 Date: 2021-01-15 Source: ResearchSquare

    BackgroundMuch remains unknown about COVID-19 MESHD onset and rehabilitation's symptomatic features, especially the long-term health consequences of patients with COVID-19 MESHD who have been discharged from the hospital.MethodsIn this cohort study, we collected the first pandemic data of hospitalized patients in Wuhan from February 20 to March 31, 2020. All patients completed a 3-month follow-up after discharge. We carefully analyzed the detailed symptomatic characteristics of severe COVID-19 MESHD at illness onset and three months after discharge, compared it with non-severe patients, and used multiple logistic regression to determine potential symptomatic risk factors for severe COVID-19 MESHD.ResultsA total of 932 hospitalized patients with COVID-19 MESHD were enrolled, including 52 severe cases and 880 non-severe cases. Fever MESHD (60%), cough (50.8%), and fatigue MESHD (36.4%) were the most common symptoms, followed by anorexia MESHD (21.8%) and dyspnea MESHD (19.2%). The median duration of fever MESHD was seven days, which was characterized by persistent low fever MESHD. The median duration of cough MESHD was 17 days, characterized by dry cough MESHD without sputum. Most dyspnea MESHD occurred on the fourth day after symptom onset, with a median duration of 16 days. The incidences of taste loss and olfactory disturbance MESHD were only 6.2% and 3.1%, respectively. Multivariate logistic regression analysis showed that age over 65 years old (OR 6.52, 95% CI 3.27-13.02, P<0.0001), male sex (3.71, 1.90-7.26, P = 0.0001), fever MESHD lasting for more than five days (1.90, 1.00-3.62, P=0.0498), anorexia MESHD at onset (2.61, 1.26-5.40, P=0.0096), and modified Medical Research Council level above grade 2 when dyspnea MESHD occurred (14.19,7.01-28.71, P<0.0001) were symptomatic risk factors for severe COVID-19 MESHD. Three months after discharge from the hospital, 6.2% of patients still cough, 7.2% of patients still dyspnea MESHD, and 1.8% still fatigue MESHD, and 1.5% of patients had olfactory or taste disorders MESHD.Conclusions COVID-19 MESHD caused clusters of symptoms, with multiple systems involved. Specific symptomatic features at the onset of illness have predictive value for severe COVID-19 MESHD. Persistent legacy symptoms are more frequent in severe COVID-19 MESHD patients.

    Risk factors for critical outcome of COVID-19 MESHD differ according to location: a systematic review and meta-analysis

    Authors: Hyung-Jun Kim; Hyeontaek Hwang; Hyunsook Hong; Jae-Joon Yim; Jinwoo Lee

    doi:10.21203/rs.3.rs-133535/v1 Date: 2020-12-21 Source: ResearchSquare

    Background The mortality rates of the coronavirus disease 2019 MESHD ( COVID-19 MESHD) differ across the globe. While some risk factors for poor prognosis of the disease are known, regional differences are suspected. We reviewed the risk factors for critical outcomes in extensive number of studies according to the study location.Methods We searched the PubMed, Embase, Cochrane Library, and Web of Science literature databases from January 1, 2020 to June 8, 2020. We defined the critical outcome as death MESHD, admission to the intensive care unit, or critical type of COVID-19 MESHD. Candidate variables to predict the critical outcome included patient demographics, underlying medical condition, symptoms, and laboratory findings. Pooled relative risks (RRs) and standardized mean differences were calculated for each variable and were also determined according to the study’s continent.Results A total of 80 studies were included from Asia (n = 48), Europe (n = 22), and North America (n = 10). The risk factors for the critical outcome in the overall population included male sex, age, and all inspected underlying medical conditions. Symptoms of dyspnea MESHD, anorexia MESHD, dizziness MESHD, fatigue MESHD, and certain laboratory findings were also indicators of the critical outcome. Subgroup analysis was performed according to study location, and we found several discrepancies. Underlying respiratory disease was associated higher risk of the critical outcome in studies from Asia (pooled RR 2.16 [1.60–2.92] and Europe (pooled RR 1.50 [1.32–1.69]), but not North America. Underlying hepatic disease was associated with a higher risk of the critical outcome from Europe (pooled RR 1.34 [1.15–1.56]), but not from Asia and North America. Symptoms of vomiting (pooled RR 2.43 [1.60–3.69]), anorexia (pooled RR 2.38 [1.45–3.91]), dizziness (pooled RR 2.23 [1.51–3.28]), and fatigue (pooled RR 1.92 [1.23–3.02]) were significantly associated with the critical outcome in studies from Asia, but not from Europe and North America. Hemoglobin and platelet count affected patients differently in Asia compared to those in Europe and North America.Conclusions There are several discrepancies among risk factors for critical outcomes among patients with COVID-19 MESHD according to the location of the infected patient.

    COVID-19 MESHD phobia MESHD in a boy with undiagnosed autism spectrum disorder MESHD: a case report

    Authors: Shoko Sakamoto; Dai Miyawaki; Ayako Goto; Yuji Harima; Daisuke Tokuhara; Koki Inoue

    doi:10.21203/rs.3.rs-120411/v1 Date: 2020-12-02 Source: ResearchSquare

    BackgroundThe coronavirus disease MESHD ( COVID-19 MESHD) is affecting mental health profoundly. Previous studies have reported pandemic-related anxiety MESHD. Anxiety disorder MESHD and autism spectrum disorder MESHD ( ASD MESHD) are relatively common comorbidities. However, thus far, there is no report of any patient with undiagnosed ASD MESHD who developed anxiety disorders MESHD caused by the COVID-19 pandemic MESHD.Case presentationIn this case report, we describe an 8-year-old Japanese boy with undiagnosed ASD MESHD who developed COVID-19 MESHD phobia MESHD, resulting in avoidant restrictive food intake disorder MESHD ( ARFID MESHD). As COVID-19 MESHD was highly publicized in the mass media and the risk of droplet infection was emphasized upon, the patient began to fear viral contamination from food, culminating in a refusal to eat or even swallow his saliva. He was admitted to a pediatric medical center in Osaka with life-threatening dehydration MESHD and was then referred to our child psychiatry department for treatment. We clinically diagnosed the patient with COVID-19 MESHD phobia resulting in ARFID. We identified the characteristics of ASD MESHD from his present social communication skills and developmental history. We provided psychoeducation of ASD MESHD for the parents as well as administered supportive psychotherapy for the patient. Shortly after our intervention, which was designed to relieve his ASD MESHD-related anxiety MESHD, his dysphagia MESHD improved. Our findings suggest that children with undiagnosed ASD MESHD may develop COVID-19 MESHD phobia MESHD. In these cases, intervention for ASD MESHD, such as sharing information with parents and teachers to explain what autism MESHD is and how it is likely to affect the child’s development and function, and to make an individual education plan may be more appropriate than starting treatment for anxiety disorders MESHD as the first-line option.Conclusion COVID-19 MESHD is the biggest pandemic in the recent past and more undiagnosed ASD MESHD patients who develop COVID-19 MESHD phobia MESHD may seek treatment. Clinicians should consider the underlying ASD MESHD in these patients and assess their developmental history, such as joint attention, as well as their present social communication skills.

    Determinants of Persistent Post COVID-19 MESHD symptoms: Value of a Novel COVID-19 MESHD symptoms score

    Authors: islam Galal; Aliae AR Mohamed-Hussein; - Mariam T Amin; - Mahmoud M Saad; Hossam Eldeen E Zayan; - Mustafa Z Abdelsayed; - Mohamed M Moustafa; - Abdel Rahman Ezzat; - Radwa ED Helmy; - Howaida K Abd- Elaal; - Nasrallah A Al Massry; - Mohamed A Soliman; - Asmaa M Ismail; - Karima MS Kholief,; - Enas Fathy; - Maiada K Hashem

    doi:10.1101/2020.11.11.20230052 Date: 2020-11-12 Source: medRxiv

    Background: Being a newly emerging disease MESHD little is known about its long-lasting post COVID-19 MESHD consequences. Aim of this work is to assess the frequency, patterns and determinants of persistent post COVID-19 MESHD symptoms and to evaluate the value of a proposed Novel COVID-19 MESHD symptoms score. Patients with confirmed COVID-19 MESHD in the registry were included in a cross sectional study. The patient demographics, comorbid disorders, the mean duration since the onset of the symptoms, history of hospital or ICU admittance, and treatment taken during acute state, as well as symptoms score before and after convalescence were recorded. Results: The most frequent constitutional and neurological symptoms MESHD were myalgia MESHD (60.0%), arthralgia MESHD (57.2%), restriction of daily activities (57.0%), sleeping troubles (50.9%), followed by anorexia MESHD (42.6%), chest pain MESHD (32.6%), gastritis MESHD (32.3%), cough (29.3%) and dyspnea MESHD (29.1%). The mean total score of acute stage symptoms was 31.0 while post COVID 19 symptoms score was 13.1(P<0.001). The main determinants of the persistent post COVID-19 MESHD symptoms were the need for oxygen therapy (P<0.001), pre-existing hypertension MESHD (P=0.039), chronic pulmonary disorders MESHD (P=0.012), and any chronic comorbidity (P=0.004). There was a correlation between the symptom score during the acute attack and post COVID-19 MESHD stage (P<0.001, r=0.67). The acute phase score had 83.5% sensitivity and 73.3% specificity for the cutoff point > 18 to predict occurrence of Post- COVID-19 MESHD symptoms. Conclusions: COVID-19 MESHD can present with a diverse spectrum of long-term post COVID-19 MESHD symptoms. Increased acute phase symptom severity and COVID-19 MESHD symptom score > 18 together with the presence of any comorbid diseases increase the risk for persistent post COVID-19 MESHD manifestations and severity. Keywords: Post- COVID-19 MESHD symptoms; symptom score; COVID-19 MESHD symptom score; comorbidities; persistent symptoms.

    SARS-CoV-2 antibody prevalence and symptoms in a local Austrian population

    Authors: Dennis Ladage; Yana Hoeglinger; Dorothee Ladage; Christoph Adler; Israfil Yalcin; Ralf Braun

    doi:10.1101/2020.11.03.20219121 Date: 2020-11-04 Source: medRxiv

    Background: Since December 2019 the novel coronavirus (SARS-CoV-2) is the center of global attention due to its rapid transmission and toll on health care systems and global economy. Population-based serosurveys measuring antibodies for SARS-CoV-2 provide one method for estimating infection rates and monitoring the progression of the epidemic. Methods: In June 2020 we succeeded in testing almost half of the population of an Austrian township (n=835 of 1359 inhabitants) with a reported higher incidence for COVID-19 MESHD infections. We determined the level of prevalence for SARS-CoV-2 in this population, factors affecting, and symptoms correlated with prior infection. Results: We found a high prevalence of 9% positive antibodies among the town population in comparison to 6% of the neighboring villages. Only 20% of SARS-CoV-2 cases self-declared being asymptomatic. In contrast, we identified six single major symptoms, including anosmia/ageusia MESHD, weight loss MESHD, anorexia MESHD, general debility, dyspnea MESHD, and fever MESHD, and especially their combination to be of high prognostic value for predicting SARS-CoV-2 infection MESHD in a patient. Our comparison of the gold standard lab-based ELISA test and the on-site antibody test demonstrated a lack of accuracy for the latter test form. Conclusions: This population study demonstrated a high prevalence of antibodies to SARS-CoV-2 as a marker of both active and past infections in an Austrian township. Several symptoms revealed a diagnostic value especially in combination. Results from self-administered antibody tests should be considered with caution.

    Necrotising Vasculitis in Covid-19 MESHD: watch out for bowel perforation

    Authors: Tonia Persiano; Francesca Grulli; Pietro Cornara; Francesca Bonomi; Alberto Casazza; Anna Coci; Sabina Teresa Mediani; Elisabetta Bellazzi; Livio Carnevale

    doi:10.21203/rs.3.rs-79258/v1 Date: 2020-09-17 Source: ResearchSquare

    Introduction: SARS-Cov-2 infection MESHD can be asymptomatic, greatly impair respiratory function and, sometimes, affect other organs. Gastro-enteric involvement seems to be not so rare and many patients suffered for abdominal pain MESHD, anorexia MESHD, nausea MESHD and vomiting MESHD, diarrhoea MESHD or jaundice MESHD. Case presentation: Here we report a case of a Covid-19 MESHD patient who developed a right colon MESHD perforation due to a pseudomembranous colitis MESHD without Clostridium Difficile toxins finding associated to a necrotising vasculitis MESHD. In this patient a PCR test performed on gastric fluid showed SARS-CoV-2 enteric replication. Discussion: Necrotizing vasculitis MESHD is an anatomopathological typical findings in Covid-19 MESHD. It has been documented in several organs and tissues. In our case, evident foci of necrotizing vasculitis MESHD with intravascular obliteration by fibrin thrombi with macrophagic cells infiltration are anatomopathological findings of a CD toxins free pseudomembranous colitis MESHD leading to bowel perforation. Conclusions: Bowel perforation due to necrotizing vasculitis MESHD leading to pseudomembranous colitis MESHD could be a SARS-Cov-2 related clinical finding.

    Clinical characteristics study of elderly patients aged 75 or older with COVID-19 MESHD pneumonia in China

    Authors: Chao Zhang; Hua Fu; Long Zhang; Yuxiong Yin; Jing Lin; Hu Liu; Qing Mao

    doi:10.21203/rs.3.rs-67737/v1 Date: 2020-08-28 Source: ResearchSquare

    Background: Coronavirus disease 2019 MESHD ( COVID-19 MESHD), a newly emerged respiratory disease MESHD caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has recently become pandemic. Clinical observation indicated that elderly patients had high incidence of severe pneumonia MESHD and poor treatment efficacy. Therefore, this study was to clarify the characteristics of elderly patients aged 75 or older with COVID-19 MESHD pneumonia MESHD in order to guide rational treatment for elderly patients. Methods: we enrolled 331 elderly patients aged 75 or older with confirmed COVID-19 MESHD in Huoshenshan hospital of Wuhan from February 3rd to March 31st. The cases were divided into general, serious and critical groups according to severity after hospitalization, and the difference among groups were compared by R package statistics software. Results: Compared with general group, serious and critical groups had more underlying comorbidities and higher incidence of cough MESHD, breath shortness MESHD and anorexia MESHD. Moreover, there existed obviously differences in many of laboratory indexes and CT images among them. serious and critical elderly patients were more likely to receive oxygen, mechanical ventilation, expectorant, corticosteroid, abidor, cephaloprin, imipenem, human serum albumin HGNC (HSA), nutrition support, anti SARS-CoV-2 positive plasma and actemra. Multivariate analysis of factors showed that male sex, hypertension MESHD, diabetes MESHD, renal diseases MESHD, breath shortness MESHD, neutrophil, platelet, creatinine, lactate dehydrogenase were the risk factor for serious and critical illness. While blood cell (WBC) was the protective factor. Conclusion: elderly patients have high incidence of severe pneumonia MESHD and poor treatment efficacy. The reasons might be that many of the elderly patients with COVID-19 MESHD pneumonia MESHD have certain chronic disease MESHD, poor immune function and a meager response to the virus. the pathogenic mechanism of SARS-CoV-2 might be involved in the cell-mediated immunity and cytokine storms by acting on lymphocytes.

    Prevalence and correlation of symptoms and comorbidities in COVID-19 MESHD patients: A systematic review and meta-analysis

    Authors: Mohammad Meshbahur Rahman; Badhan Bhattacharjee; Zaki Farhana; Mohammad Hamiduzzaman; Muhammad Abdul Bake Chowdhury; Mohammad Sorowar Hossain; Mahbubul H Siddiqee; Md. Ziaul Islam; Enayetur Raheem; Md. Jamal Uddin

    doi:10.1101/2020.08.19.20177980 Date: 2020-08-22 Source: medRxiv

    Background: The COVID-19 MESHD affected millions of people, and the patients present a constellation of symptoms and comorbidities. We aimed to chronicle the prevalence and correlations of symptoms and comorbidities, and associated covariates among the patients. Methods: We performed a systematic review and meta-analysis [PROSPERO registration: CRD42020182677]. Databases [PubMed, SCOPUS, EMBASE, WHO, Semantic Scholar, and COVID-19 MESHD Primer] were searched for clinical studies published in English from January 1 to April 20, 2020. The pooled prevalence of symptoms and comorbidities were identified using the random effect model, and sub-groups analysis of patients age and locations were investigated. A multivariable factor analysis was also performed to show the correlation among symptoms, comorbidities and age of the COVID-19 MESHD patients. Findings: Twenty-nine articles [China (24); Outside of China (5)], with 4,884 COVID-19 MESHD patients were included in this systematic review. The meta-analysis investigated 33 symptoms, where fever MESHD [84%], cough/dry cough MESHD [61%], and fatigue/weakness MESHD [42%] were found frequent. Out of 43 comorbidities investigated, acute respiratory distress syndrome MESHD ( ARDS MESHD) [61%] was a common condition, followed by hypertension MESHD [23%] and diabetes MESHD [12%]. According to the patients age, the prevalence of symptoms like fatigue MESHD/weakness, dyspnea/shortness of breath MESHD, and anorexia MESHD were highly prevalent in older adults [[≥]50 years] than younger adults [<50 years]. Diabetes MESHD, hypertension MESHD, coronary heart disease MESHD, and COPD MESHD/ lung disease MESHD were more prevalent comorbidities in older adults than younger adults. The patients from outside of China had significantly higher prevalence [p<0.005] of diarrhea MESHD, fatigue MESHD, nausea MESHD, sore throat, and dyspnea MESHD, and the prevalent comorbidities in that region were diabetes MESHD, hypertension MESHD, coronary heart disease MESHD, and ARDS MESHD. The multivariable factor analysis showed positive association between a group of symptoms and comorbidities, and with the patients age. Interpretation: Epitomizing the correlation of symptoms of COVID-19 MESHD with comorbidities and patients age would help clinicians effectively manage the patients.

    Coinfection with SARS-CoV-2 and dengue virus: a case report

    Authors: Prasetyo Hariadi; Dewi Lokida; Adhella M Naysilla; Nurhayati Lukman; Herman Kosasih; Yan Mardian; Gestana Andru; Inggar Pertiwi; Retna I Sugiyono; Antonius A Pradana; Gustiani Salim; Deni P Butar-butar; Chuen-Yen Lau; Muhammad Karyana

    doi:10.21203/rs.3.rs-63867/v1 Date: 2020-08-21 Source: ResearchSquare

    Background: Since its emergence in China, SARS-CoV-2 has infected more than 15.5 million people worldwide, including in regions where dengue virus (DENV) is hyperendemic such as Latin America and Southeast Asia, including Indonesia. Hence, anticipation for simultaneous infection by DENV and SARS-CoV-2 has been raised.Case presentation: We describe a 68-year-old woman with diabetes mellitus type II MESHD who was admitted to the Tangerang District Hospital on 14 April 2020. She lived in a neighborhood where a few people were contracting dengue fever MESHD. She presented with five days of fever MESHD, malaise MESHD, anorexia MESHD, nausea MESHD, myalgia MESHD, and arthralgia MESHD. Hematology results revealed anemia MESHD, thrombocytopenia MESHD, normal leukocyte count, increased neutrophil proportion, and decreased lymphocyte proportion and absolute lymphocyte. Her chest X-ray showed right pericardial infiltrates. Although dengue was clinically suspected, as she met COVID-19 MESHD screening criteria, she was also tested for SARS-CoV-2 infection MESHD. The patient was treated with ceftriaxone, paracetamol, azithromycin, oseltamivir, and chloroquine. She was clinically improved four days later and was discharged from the hospital on 25 April 2020 after SARS-CoV-2 rRT-PCR was negative on two consecutive samples. Dengue was diagnosed retrospectively based on sero-conversion of dengue IgM and a very high dengue IgG index (Focus Diagnostics®, ELISA), and sero-conversion of dengue IgM and positive IgG (PanBio ®Dengue duo cassette), which was equivalent to high hemagglutination inhibition antibody titer found in secondary dengue infection MESHD.Conclusion: The overlapping clinical presentations of COVID-19 MESHD and dengue; limited diagnostic capacity of laboratories in resource constrained settings; and complexities of interpreting results make identification of COVID-19 MESHD in the dengue endemic setting challenging. Clinicians in endemic areas must maintain a high index of suspicion for the possibility of COVID-19 MESHD coinfection with DENV and other tropical pathogens.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.